Drugs moving into the clinic: 6

By Mike Nagle

- Last updated on GMT

Related tags Cancer Hepatitis b Leukemia

The sixth in a series of periodic roundups of drugs that have moved
from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
Pharmacopeia & Schering-PloughPS522501metabolic diseases Schering-Plough refused to comment
Callisto PharmaceuticalsL-AnnamycinOncology - refractory or relapsed acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML) in paediatric patientsAnthracyclines inhibit DNA & RNA synthesis by intercalating between base pairs & prevent cell replication. NB earlier Phase I trial in adults
Peregrine Pharmaceuticals & anonymous licenseeundisclosedoncology European trial of drug designed using tumour necrosis therapy technology
Cytogen CorporationCYT-500oncology - prostate cancermonoclonal antibody targeted to prostate-specific membrane antigen (PSMA) and carrying Lutetium 177
Panacos PharmaceuticalsPA-1050040 (a.k.a. PA-040)HIVHIV maturation inhibitor.' Acts at same point in HIV lifecycle as protease inhibitors but attaches to GAG complex preventing cleavage of capsid protein and SP1. Thus, hoped to still be effective on resistant viral strains. NB. Analogue of PA-457, a first-in-class compound in Phase IIb trials.
Dynavax Technologiesunnamedchronic hepatitis B viruscombines, for the first time, the surface and core antigen of HBV. Based on short, synthetic oligonucleotides to activate toll-like receptor 9 and induce immune response.
Sunesis PharmaceuticalsSNS-314oncologySmall molecule aurora kinase A, B, and C inhibitor to prevent cancer cell growth and division NB. Investigational New Drug (IND) application
AlkermesALKS 29Addiction - Alcohol DependanceUndisclosed. NB Phase I/II trial.

Related topics Preclinical Research

Related news